Journal Article

Efficacy and Safety of Clarithromycin as Treatment for Mediterranean Spotted Fever in Children: A Randomized Controlled Trial

Antonio Cascio, Claudia Colomba, Domenico Di Rosa, Ludovico Salsa, Lucio di Martino and Lucina Titone

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 33, issue 3, pages 409-411
Published in print August 2001 | ISSN: 1058-4838
Published online August 2001 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/321864
Efficacy and Safety of Clarithromycin as Treatment for Mediterranean Spotted Fever in Children: A Randomized Controlled Trial

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

Fifty-one children with Mediterranean spotted fever (MSF) were randomized to receive either clarithromycin, 15 mg/kg/day orally in 2 divided doses, or chloramphenicol, 50 mg/kg/day orally in 4 divided doses, for 7 days. Mean time to defervescence was 36.7 h in the clarithromycin group and 47.1 h in the chloramphenicol group (P = .047). Clarithromycin could be an acceptable therapeutic alternative to chloramphenicol and to tetracyclines for children aged <8 years with MSF.

Journal Article.  1875 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.